In a byline article for Pharma IQ, Goodwin partner Natasha Daughtrey, who serve in the Intellectual Property Litigation group, share insight on how European developers can successfully launch a biosimilar in the U.S. Read the article here.
Related Content
- AlertFebruary 27, 2023
NLRB Concludes that Separation Agreement Provisions Prohibiting Disparagement and Requiring Confidentiality of Agreement Terms Violate Employee Rights
- In the PressJanuary 27, 2023
Cannabis Marketing Proposed Regulations in New York & Neighboring States (Bloomberg Law)
- AlertJanuary 6, 2023
FTC Proposes a Sweeping Rule That Would Ban Nearly All US Noncompete Agreements
- Goodwin InsightsSeptember 20, 2022
3 Reasons Beauty Cos. Should Consider Pursuing Patents
- AlertAugust 10, 2022
Recent Court Decisions Shed Light on Enforceability of Electronic Contracts in the U.S.
- AlertJuly 28, 2022
Chief Judge of Western District of Texas Changes Waco Patent Case Assignment System
- AlertJuly 7, 2022
Fintiv 2.0: USPTO Director Issues Guidance Softening Risk of Discretionary Denial
- AlertMay 6, 2022
U.S. Government Authorizes Transactions Related to Patent Protection in Russia
- WebinarSeptember 26, 2023
Unconscious Bias Through the Lens of Pop Culture
- Speaking EngagementsMay 10, 2023
AIPLA 2023 Spring Meeting
- WebinarMarch 28, 2023
Reactions to Amgen v. Sanofi and the Future of Patent Law’s Enablement Requirement
- Press ReleaseMarch 24, 2023
Berkshire Grey Enters Into Definitive Merger Agreement with SoftBank Group
- In the PressMarch 24, 2023
Amgen Supreme Court Arguments Aren't Just About Biology (Law360)
- In the PressMarch 23, 2023
Biopharma Industry Sharply Divided Over Supreme Court Antibody Patent Brawl (Pink Sheet)
- In the PressMarch 22, 2023
Goodwin Snags Tech and Life Sciences Litigation Trio (Commercial Dispute Resolution)
- In the PressMarch 22, 2023
Goodwin Adds 3 IP Litigators In NY (Law360)